Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-06T10:10:44.505Z Has data issue: false hasContentIssue false
  • English
  • Français

P0038 - A Randomized and double-blinded clinical trial of Venlafaxine HCL sustained release capsules for treatment in adolescents with major depression

Published online by Cambridge University Press:  16 April 2020

W.D. Ji ,
H.F. Chang ,
S.C.H. Yang ,
C.H. Yang ,
X.Q. Huang ,
J.X. Zhou  and
T.Y. Guo
W.D. Ji
Affiliation:
Department of Psychiatry, Changning Mental Health Center, Shanghai, China The Hospital of Bio-X Center of Shanghai Jiaotong University, Shanghai, China
H.F. Chang
Affiliation:
Department of Psychiatry, Changning Mental Health Center, Shanghai, China The Hospital of Bio-X Center of Shanghai Jiaotong University, Shanghai, China
S.C.H. Yang
Affiliation:
Henan Mental Health Center, Xinxiang, China
C.H. Yang
Affiliation:
Wenzhou Medical College, Wenzhou, China
X.Q. Huang
Affiliation:
West China University of Medical Science, Chengdu, China
J.X. Zhou
Affiliation:
Shenzhen Children's Hospital, Shenzhen, China
T.Y. Guo
Affiliation:
Shenzhen University, Shenzhen, China

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aims:

To evaluate the efficacy and safety of venlafaxine HCL sustained release capsules in treatment of depression in adolescents.

Methods:

A randomized，double blind and double dummy clinical trial enrolled 60 adolescents patients with depression, who were randomized 1:1 to administer venlafaxine HCL sustained release capsules 150 mg or fluoxetine 20 mg daily for 8 weeks．The efficacy of both treatment groups was evaluated based on the Hamilton Depression Scale and Clinical General Impression Scale pre- and post-treatment.

Results:

The scores of Hamilton Depression Scale at the end of therapy were significantly reduced compared with the baseline in both groups(P<0.01).The efficacy rate of venlafaxine HCL sustained release capsules versus fluoxetine treatment was 70.0％ and 65.5％, respectively;the P value showed no statistical difference(P>0.05).The common adverse reactions included dry mouth，insomnia，dizziness，and loss of appetite.

Conclusion:

Venlafaxine HCL sustained release capsules is efective and safe agent for adolescents with major depression.

Type
Poster Session II: Antidepressants
Information
European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S203
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.